Technetium-99m mertiatide (MAG3) is highly protein-bound but reversibly so, and is rapidly cleared from blood by renal tubular secretion and glomerular filtration. Dynamic renal uptake and excretion are measured by scintigraphy to assess perfusion, function and urinary drainage.
Indications / reported uses
Renal scintigraphy to evaluate congenital or acquired renal abnormalities, renal failure, urinary tract obstruction and renal calculi in adults and children.
Provides information on overall and split renal function, renal angiograms and renogram curves for whole kidney and renal cortex.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Mertiatide Environmental Risk Assessment (ERA) (the Mertiatide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.